Eumentis Therapeutics, Inc. — Form D
Eumentis Therapeutics, Inc. of NEWTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2022-04-15. The offering totals $5.0M, of which $5.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-04-15
- Form: D
- Accession: 0001823359-22-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $5.0M
- Minimum investment: $5.0M
- Investors: 1
- Date of first sale: 2022-04-13
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-442084
Issuer
- Name: Eumentis Therapeutics, Inc.
- CIK: 0001823359
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 508 DUDLEY ROAD, NEWTON, MA, 02459
- Phone: 6174133020
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Amar Kapur | Director | Newton, MA |
| Maryann Bryla | Director | Newton, MA |
| James Larrick | Director | Osage Beach, MO |
| Randall Marshall | Executive Officer | Newton, MA |
| Kim Patrick | Director | Newton, MA |
| Mark Tepper | Director | Newton, MA |
| Mark Tepper | Executive Officer | Newton, MA |
| Andrew Pearlman | Director | Newton, MA |
Other filings by this issuer (3)
More